Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®
- Strong recruitment momentum demonstrated in 2026
- Year-to-date recruitment has already surpassed total enrollment for 2025
Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.
